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Abstract Phosphorylation of the human prostacyclin (PGI2)
receptor (hIP-R) by diacylglycerol-regulated protein kinase C
(PKC) has been reported to be responsible for its rapid
desensitization in HEK293 cells. In this study we demonstrate,
that human fibroblasts reveal a much slower hIP-R desensitiza-
tion kinetics, which was neither affected by stimulation nor
inhibition of PKC by either phorbol 12-myristate-13-acetate or
GF-109203X suggesting a different cellular mechanism.
Although agonist-promoted sequestration of a C-terminally
green fluorescent protein-tagged hIP-R was demonstrated, it
did not account for the long-term desensitization. Concanavalin
A did not abolish, but accelerated receptor desensitization
kinetics. Resensitization of hIP-R involved receptor recycling
and/or de novo synthesis of receptor protein, depending on the
duration of prior desensitization. This is the first study
investigating the mechanisms of hIP-R desensitization in intact
human cells naturally expressing hIP-R. Our data suggest, that a
hitherto unknown mechanism of hIP-R long-term desensitization,
which is independent of receptor phosphorylation by conventional
and novel type PKC isoforms or endocytosis, is a key event in
regulating the cellular responsiveness to PGI2. ß 2000 Feder-
ation of European Biochemical Societies. Published by Elsevier
Science B.V. All rights reserved.
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1. Introduction
Prostacyclin (PGI2), the major arachidonic acid metabolite
produced in vascular cells, exerts its biological actions via a
speci¢c receptor (IP-R), which belongs to the family of G
protein-coupled receptors (GPCRs). IP-R may couple to mul-
tiple G protein/e¡ector systems, including cyclic adenosine
monophosphate (cAMP) formation via Gs and IP3 formation
via Gi [1]. PGI2 and several mimetics have been used for a
number of clinical indications, including pulmonary hyperten-
sion [2], peripheral arterial occlusive disease and others [3].
Although short-term administration of PGI2 induced bene¢-
cial e¡ects, they were less pronounced after more chronic use.
These ¢ndings may be explained by a time-dependently re-
duced IP-R responsiveness to repeated agonist challenge, re-
ferred to as receptor desensitization. To understand the mech-
anism underlying this desensitization is of major interest and
might result in signi¢cant improvement of therapeutical e⁄-
cacy of PGI2 mimetics.
Termination of the signal after agonist challenge is essential
for GPCRs. The prototypical model for GPCR regulation
involves three key mechanisms [4]. The ¢rst and most rapid
phase of desensitization occurs within seconds to minutes
after exposure to agonist and is due to agonist-induced recep-
tor phosphorylation mediated by second messenger kinases,
such as PKA and protein kinase C (PKC) or G protein-
coupled receptor kinase (GRKs), eventually uncoupling the
receptor from its G protein. This event, referred to as short-
term desensitization, is followed by sequestration of the re-
ceptor away from the cell surface [5^7]. Finally, more pro-
longed receptor stimulation may cause a net decrease in total
receptor number at the membrane surface, often accompanied
by degradation of receptor protein, termed down-regulation.
The human IP-R, overexpressed in HEK293 cells, exhibits
rapid agonist-induced desensitization occurring within min-
utes [8,9]. This process involves phosphorylation of the C-
terminal tail by PKC and thus seems to follow the general
paradigm of GPCR signal attenuation. In contrast to this
short-term desensitization, cell systems naturally expressing
IP-R reveal a much slower time course of desensitization re-
quiring 3^10 h [10^13]. The mechanism involved in this ago-
nist-induced long-term attenuation is still poorly understood
and was investigated in the present study.
2. Material and methods
2.1. Materials
All cell culture reagents, TRIzol1 and LipofectAMINE PLUS1
were purchased from Gibco Life Technologies (Karlsruhe, Germany).
Iloprost was kindly provided by Schering (Berlin, Bergkamen, Ger-
many). Isoproterenol, cycloheximide, phorbol 12-myristate-13-acetate
(PMA) and isobutylmethylxanthine (IBMX) were purchased from
Sigma (Deisenhofen, Germany). GF-109203X was from Alexis (Gru«-
nenberg, Germany). All antibodies were from Santa Cruz Biotechnol-
ogy (Santa Cruz, CA, USA). The L2AR cDNA (human), GRK 2
(bovine) and GRK 5 (bovine) cDNAs were a generous gift from
Dr. N.J. Freedman (Duke University, Durham, NC, USA).
2.2. Cell culture and transfections
Human ¢broblasts CRL1635 were obtained from ATCC (Mana-
ssas, VA, USA). Fibroblasts were grown in Dulbecco’s modi¢ed Ea-
0014-5793 / 00 / $20.00 ß 2000 Federation of European Biochemical Societies. Published by Elsevier Science B.V. All rights reserved.
PII: S 0 0 1 4 - 5 7 9 3 ( 0 0 ) 0 2 1 5 6 - 6
*Corresponding author. Fax: (49)-211-81 14781.
E-mail: kschroer@uni-duesseldorf.de
Abbreviations: cAMP, cyclic adenosine monophosphate; c-, conven-
tional; GFP, green £uorescent protein; GRK, G protein-coupled re-
ceptor kinase; GPCR, G protein-coupled receptor; hIP-R, human
prostacyclin receptor; n-, novel; PGI2, prostacyclin; PKC, protein
kinase C; PMA, phorbol 12-myristate-13-acetate
FEBS 24260 6-11-00 Cyaan Magenta Geel Zwart
FEBS 24260 FEBS Letters 484 (2000) 211^216
gle’s high glucose medium supplemented with 10% fetal bovine serum,
100 Wg/ml streptomycin and 100 units/ml penicillin. All cDNAs were
cloned into the mammalian expression vector pcDNA3 for transfec-
tion. For transient transfection cells were grown to 50^80% con£u-
ency and transfected with 1 Wg DNA/6 well using 4 Wl LipofectAM-
INE and 6 Wl PLUS reagent. In case of GRK 2 and GRK 5
overexpression, cells were split the day after transfection into 24-
well dishes and assayed the following day.
2.3. cAMP measurements
Fibroblasts were grown to 90% con£uency in 24-well plates. After
preincubation in HBSS containing 1 mg/ml BSA, 10 mM HEPES (pH
7.3) and 1 mM IBMX for 10 min at 37‡C, cells were stimulated with
100 nM iloprost for the indicated times. Reactions were stopped by
aspiration and addition of ice-cold 96% ethanol. Dried samples were
overlaid with 300 Wl RIA-bu¡er (150 mM NaCl, 8 mM Na2HPO4,
2 mM NaH2PO4, pH 7.4) and frozen overnight at 380‡C. cAMP in
the supernatant was determined by radioimmunoassay [14]. For de-
sensitization assays cells were pretreated with 100 nM iloprost for the
indicated times and washed three times with HBSS. cAMP formation
was then measured as described [14]. Concanavalin A (0.25 Wg/ml),
PMA (2 WM) and GF-109203X (1 WM) were added 15 min prior to
iloprost during the desensitization procedure. For resensitization stud-
ies, cells were desensitized by 6 h treatment with 100 nM iloprost.
Iloprost was removed by three rapid washes with medium (w/o FCS),
fresh medium was added, and the cells were placed in a CO2 incuba-
tor for the indicated periods of time. Cycloheximide (50 Wg/ml) was
present during the resensitization procedure. Cells were then chal-
lenged with iloprost and cAMP measurements were performed as
described above. Protein determination was performed according to
the method of Bradford [15] and adenylyl cyclase activity was ex-
pressed as pmol cAMP mg31 protein.
2.4. Generation of the human PGI2 receptor (hIP-R)^green £uorescent
protein (GFP) construct
The GFP was fused in-frame to the C-terminal end of hIP-R by
means of PCR. Using the hIP-R cDNA as template, the ¢rst PCR was
performed applying a sense oligonucleotide, containing an internal
hIP sequence 5P-AGCAGTACTGCCCCGGCAGCTGGTGCTTCC-
3P and a receptor speci¢c antisense oligonucleotide (5P-GTCAGCTT-
GAAGATATCGCAGAGGGAG-3P), containing an EcoRV site
(underlined) instead of the original TGA stop codon. The 0.7-kb
PCR product was digested with EcoNI/EcoRV and ligated into
pcDNA3. The resulting plasmid (pc3hIP-Rmut) contained hIP-R
without the C-terminal EcoNI/EcoRV fragment. In a second PCR
reaction the GFP sequence was generated from the plasmid
pEGFP-C1 (Clontech, Heidelberg, Germany) using a sense oligonu-
cleotide, containing an EcoRV site (underlined) upstream of the GFP
start codon (bold letters): 5P-TGCGATATCATGGTGAGCAAG-
GGCGAG-3P and an antisense oligonucleotide, containing a XhoI
site (underlined) located 3P of the GFP stop codon (bold letters):
5P-TCTCTCTGGAGTTATCATCCGGACTTGTACAGCTC-3P. The
second PCR product was digested with EcoRV/XhoI and ligated into
pc3hIPmut resulting in pc3hIP-R^GFP.
2.5. Confocal laser microscopy
Confocal microscopy was performed on a Leica DM IRB/E (in-
verse), DM TCS SP (confocal) laser scanning microscope, using
40U1.3 or 63U1.4 numerical aperture oil immersion lenses. Cells
were cultured on 12-mm glass coverslips and GFP £uorescence was
examined by confocal microscopy 48^72 h after transfection. For
analysis of receptor sequestration, cells were transiently transfected
with pc3hIP-R^GFP and stimulated with 100 nM iloprost.
2.6. Data analysis
Data were compared by Student’s t-test, followed by Bonferronie’s
test for multiple comparisons. A P value of 6 0.05 was considered
signi¢cant.
3. Results and discussion
3.1. IP receptor expression and desensitization in human
¢broblasts
Stimulation of human ¢broblasts with iloprost (100 nM)
resulted in a signi¢cant accumulation of cAMP (280 þ 20
pmol/(minUmg protein) vs. 2.9 þ 0.2 pmol/(minUmg protein),
n = 3), indicating the presence of functionally active IP recep-
tors. To examine whether IP-R undergoes agonist-dependent
short-term desensitization in human ¢broblasts, cells were
challenged with iloprost for increasing time periods in the
presence of 1 mM IBMX, a phosphodiesterase inhibitor,
and the amount of cAMP after each stimulation period was
measured. The kinetics of cAMP formation was comparable
to that of forskolin, a direct activator of adenylyl cyclase,
indicating that no signi¢cant short-term desensitization oc-
curred (Fig. 1A). In contrast to this, challenge of endoge-
nously expressed L2-adrenergic receptors with 100 nM isopro-
terenol resulted in a plateau of cAMP formation after 10 min,
re£ecting the known short-term desensitization of L2-adrener-
gic receptors. However, prolonged stimulation of ¢broblasts
with iloprost for 1^7 h led to a signi¢cant decrease in the
cAMP response to agonist challenge. Agonist-induced
Fig. 1. IP receptor desensitization in human ¢broblasts. A: Agonist-
stimulated cAMP generation in untreated ¢broblasts. Cells were ei-
ther unstimulated (E) or continuously stimulated with 100 nM ilo-
prost (8), 10 WM forskolin (R) or 100 nM isoproterenol (F), re-
spectively, for the indicated times. cAMP values are expressed as
percent of maximal cAMP formation during measurement. Data are
means of three independent experiments performed in triplicate.
B: Iloprost (8) or forskolin (R) stimulated cAMP generation in ¢-
broblasts pretreated with iloprost for the indicated times. cAMP
values are percent of non-desensitized control. Data are means of
three independent experiments performed in triplicate.
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cAMP formation was decreased by about 50% upon preincu-
bation with iloprost at 3 h, and by about 75% at 6 h (Fig. 1B).
When cells were challenged with forskolin (10 WM) at any
time point of iloprost pretreatment, the changes in cAMP
response did not parallel the agonist-induced desensitization
curve, rather a transient increase in cAMP formation occurred
at 1 h. Therefore, down-regulation of adenylyl cyclase as a
possible reason for reduced cAMP formation after continuous
stimulation of cells with iloprost could be excluded.
3.2. E¡ect of GRK overexpression or PKC activation on hIP-R
desensitization kinetics
In recent studies, GRKs have been shown to promote ago-
nist-stimulated desensitization of various GPCRs [16,17] with
GRK 2 and GRK 5 being the most potent enzymes [16,18].
Possible target sites for GRK-dependent phosphorylation are
also present in the amino acid sequence of the hIP-R. To
further de¢ne the role of GRKs in hIP-R desensitization, we
analyzed the e¡ect of GRK 2 and GRK 5 overexpression on
hIP-R desensitization kinetics. However, although transfec-
tion of ¢broblasts with GRK 2 and GRK 5 expression plas-
mids led to signi¢cant production of the proteins (data not
shown) they did neither attenuate receptor signaling at the
level of cAMP formation nor a¡ected hIP-R desensitization
kinetics (Fig. 2A).
Agonist-induced PKC phosphorylation of the C-terminal
tail of hIP-R dictates rapid receptor desensitization in
HEK293 cells [8]. In HEK293 cells receptor phosphorylation
was also observed if cells were treated with PMA, indicating a
role of conventional (c-) or novel (n-) type PKC isoforms.
Therefore, we investigated the e¡ect of prior c- and n-type
PKC isotype kinase activation on receptor activity and desen-
sitization kinetics in human ¢broblasts. Pretreatment of cells
for 30 min with 2 WM PMA did not result in any mitigation of
Fig. 2. E¡ect of GRK 2,5 overexpression, PKC stimulation, and
PKC inhibition on hIP-R desensitization, Iloprost-stimulated cAMP
response in ¢broblasts either without prior agonist challenge (gray
bars) or after pretreatment with 100 nM iloprost for 30 min (black
bars) or 3 h (white bars). A: Cells were transfected with the expres-
sion vector pcDNA3 containing either GRK 2 or GRK 5 or
pcDNA3 only. B: Cells were coincubated during desensitization
with the PKC inhibitor GF-109203X (1 WM) or treated with the
PKC activator PMA (2 WM), as indicated. cAMP values are ex-
pressed as percent of non-desensitized control. Data are means of
three independent experiments performed in triplicate.
Fig. 3. Sequestration of GFP-tagged hIP-R (hIP-R^GFP) in human
¢broblasts. Confocal imaging of iloprost-induced sequestration of
hIP-R^GFP in human ¢broblasts. Cells were either untreated (A) or
stimulated with iloprost for 8 h (B). Data are derived from one rep-
resentative experiment out of two with similar results.
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subsequent stimulation of cAMP formation by the IP receptor
agonist iloprost or signi¢cant acceleration of desensitization
kinetics (Fig. 2B). Furthermore, treatment of cells with the
PKC inhibitor GF-109203X (1 WM), a concentration inhibit-
ing c- and n-type PKC isoforms [19], had also no e¡ect on
desensitization kinetics (Fig. 2B). These ¢ndings suggest that
c- and n-type PKC isoforms as well as GRK 2 and GRK 5,
respectively, play only a minor if any role in hIP-R desensiti-
zation. However, a role of atypical (diacylglycerol/PMA in-
sensitive) PKC isoforms, as recently reported for the W-opioid
receptor [20], cannot be excluded in our experiments.
3.3. Sequestration of GFP-tagged hIP-R
Receptor sequestration was proved using a hIP-R^GFP fu-
sion protein. This method was applied because the expression
level of endogenously expressed hIP-R was too low to allow
ligand binding studies. Moreover, most receptor GFP fusion
proteins retain their biological activity and reveal the same
tra⁄cking pattern as the native protein [21]. Addition of
GFP to the C-terminus resulted in a functionally active recep-
tor as demonstrated by the agonist-induced cAMP formation
in transiently transfected CHO cells (not shown). In immuno-
blots, performed on cell lysates from hIP-R^GFP-expressing
¢broblasts with an antibody speci¢c to GFP, the tagged re-
ceptor appeared as a single protein band with a molecular
weight of about 70 kDa, representing the summation of the
44 kDa hIP-R plus the 27 kDa GFP-tag (not shown). Seques-
tration of hIP-R^GFP in ¢broblasts was visualized by confo-
cal microscopy 3 days after transfection. When resting cells
were studied, hIP-R^GFP was localized to the plasma mem-
branes (Fig. 3A). After stimulation with iloprost (100 nM, 8 h)
signi¢cant receptor sequestration away from the membrane
and redistribution into a distinct punctate pattern was seen
(Fig. 3B).
3.4. E¡ect of inhibitors of endocytosis on agonist-induced
desensitization kinetics
For several GPCRs, like the somatostatin receptor [22],
desensitization seems to be predominantly a consequence of
receptor sequestration away from the plasma membrane with-
out prior receptor phosphorylation. We, therefore, assayed
the e¡ect of concanavalin A, which inhibits endocytosis, on
agonist-stimulated long-term desensitization. Pretreatment of
cells with concanavalin A (0.25 Wg/ml) for 15 min prior to
stimulation with iloprost did not abolish, but rather accelerate
desensitization kinetics (Fig. 4). While continuous stimulation
of cells with iloprost (1 h) led to a reduction of cAMP for-
mation to 88% (n = 3) of control, concanavalin A pretreat-
ment reduced cAMP formation to 60% (n = 3) at the same
time point. Stimulation of cells for 3 h with iloprost led to
a reduction of cAMP formation to 54% (n = 3) of control
value, while concanavalin A pretreatment reduced cAMP for-
mation to 24% (n = 3) at the same time point. Receptor endo-
cytosis, therefore, seems not to account for the long-term
desensitization of the cAMP response to iloprost. The accel-
eration of kinetics rather indicates that receptor endocytosis
seems to be at least partly necessary for receptor resensitiza-
tion by allowing receptor recycling.
3.5. Resensitization of hIP-R
Di¡erent mechanisms may contribute to receptor resensiti-
zation after removal of agonist, namely receptor recycling
from an endosomal compartment back to the membrane
and/or de novo synthesis of receptor protein. Both mecha-
nisms have been described for hIP-R. While hIP-R in platelets
recycle, IP-R resensitization in NG 108-15 cells requires de
novo synthesis [23,24]. Our experiments revealed that with-
drawal of receptor agonist results in a slow resensitization
of IP receptors in human ¢broblasts. After treatment with
iloprost for 6 h, ¢broblasts were exposed to agonist-free con-
ditions to allow receptor resensitization. While formation of
cAMP was reduced signi¢cantly in desensitized cells and re-
mained low in the continuous presence of agonist, cAMP
formation was restored completely when cells were kept in
agonist-free medium for 18 h. Resensitization in the presence
of cycloheximide (50 Wg/ml) was only slightly reduced (Fig.
5A). In contrast, resensitization following 16 h of desensitiza-
tion was abolished by cycloheximide, suggesting that pro-
longed stimulation probably leads to receptor degradation
and/or down-regulation, making de novo receptor synthesis
a prerequisite of resensitization (Fig. 5B). It should be noted
that cycloheximide had no signi¢cant e¡ect by its own on cell
viability. It is concluded that agonist-triggered internalization
at ¢rst allows receptor recycling but prolonged stimulation
may then lead to receptor degradation, making de novo pro-
tein synthesis a prerequisite of resensitization. The observa-
tion that the duration of desensitization determines whether
recycling or degradation of receptor occurs, has been recently
described for other GPCRs including the L2-adrenergic [25,26]
and opioid receptors [27].
Perturbations at the level of PGI2 formation or at IP-R
level have been related to various cardiovascular disorders
[28^30]. Several therapeutic strategies aimed to enhance
PGI2 production and successfully reduced restenosis in di¡er-
ent animal models [31^33]. However, available data from clin-
ical trials are con£icting and currently do not support the
concept that PGI2 or stable mimetics may be successfully
Fig. 4. E¡ect of concanavalin A on agonist-induced desensitization,
Cells were subjected to desensitization as described in Fig. 1. cAMP
response was assayed in cells either untreated (gray bars) or treated
with concanavalin A (0.25 Wg/ml) (black bars) during desensitiza-
tion. Data are means of three independent experiments performed
in triplicate. *P9 0.05.
FEBS 24260 6-11-00 Cyaan Magenta Geel Zwart
S.M. Nilius et al./FEBS Letters 484 (2000) 211^216214
used to suppress restenosis after PTCA [34,35]. These ¢ndings
may be explained, at least partly, by IP-R long-term desensi-
tization. Although short-term administration of iloprost may
induce bene¢cial e¡ects, long-lasting agonist stimulation will
reduce e⁄cacy, e.g. of antiplatelet [36] or antimitogenic [12]
e¡ects of iloprost. It has been demonstrated some time ago
that inhibition of endogenous prostaglandin synthesis by in-
domethacin sensitized cells to prostaglandin administration
[37]. Thus, endogenously synthesized prostaglandins may al-
ready contribute to receptor desensitization in vivo. These
¢ndings suggest that the actual state of receptor sensitivity
in addition to the agonist concentration markedly determines
cellular e¡ects of prostaglandins.
Taken together, our data suggest that the signaling capacity
of hIP-R is attenuated by desensitization processes involving
several distinct, but overlapping mechanisms which do not
require the action of GRKs or c-/n- PKC isoforms in human
¢broblasts. Possible mechanisms may include receptor phos-
phorylation by tyrosine kinases as described for the W-opioid
receptor [38]. Moreover, as reported for the m3-muscarinic
receptor, casein kinase 1K may represent as well an alternative
pathway to GPCR phosphorylation [39]. Finally, accelerated
receptor protein degradation may result in reduced total mem-
brane receptor during long-term stimulation, thus reducing
receptor signaling. Further experiments will be necessary to
¢nd out how speci¢c desensitization of hIP-R is realized and
which cellular components of the endocytotic machinery are
involved in the internalization procedure.
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